Advertisement

Topics

FDA Accepts NDA To Review ADHD Treatment For All Age Categories

07:08 EST 13 Nov 2017 | Pharmaceutical Processing

The New Drug Application submission is supported by multiple placebo-controlled safety and efficacy studies, as well as two long-term studies that assessed the safety of dasotraline in people with ADHD for up to one year.
Contributed Author: 
Sunovion Pharmaceuticals Inc.

Original Article: FDA Accepts NDA To Review ADHD Treatment For All Age Categories

NEXT ARTICLE

More From BioPortfolio on "FDA Accepts NDA To Review ADHD Treatment For All Age Categories"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Pediatrics
Pediatrics is the general medicine of childhood. Because of the developmental processes (psychological and physical) of childhood, the involvement of parents, and the social management of conditions at home and at school, pediatrics is a specialty. With ...